[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","kzlwjdbbyx3z5qxlm1nshcopo","revision",2,"title","PDS Biotechnology Corp 更新企业简介资料","originalTitle","8-K - PDS Biotechnology Corp (0001472091) (Filer)","summary","PDS Biotechnology Corp 于 2026 年 10 月 20 日更新企业简介资料。更新内容包含最新财务信息与公司战略方向。文件已作为 8-K 报告附件提交至 SEC。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-20T23:59:06.000Z","discoveredAt","2026-10-21T10:03:53.637Z","timelineAt","category","tip","tags",[81,82,83],"stockSymbols",[80],"score",22,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f5lyvppPu4xQ",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","b21f5557-e3e8-45e0-9dd1-155d8fbd0c86","PDS Biotechnology 更新企业资料",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2026

PDS BIOTECHNOLOGY CORPORATION
\n

(Exact Name of Registrant as Specified in Charter)

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n Delaware \n \n	\n 001-37568 \n \n	\n 26-4231384 \n \n
\n \n	\n \n	\n \n
\n (State or Other Jurisdiction of Incorporation) \n	\n (Commission File Number) \n	\n (I.R.S. Employer Identification No.) \n

303A College Road East, Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following\n provisions (see General Instruction A.2. below):

\n\n\n \n\n \n\n \n\n \n\n\n

☐	\n Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) \n

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.00033 per share
\n

PDSB
\n

The Nasdaq Capital Market
\n

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter)\n or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\n revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

\n\n\n \n\n \n\n \n\n \n\n\n

Item 8.01

Other Events.

On October 20, 2026, the Company updated its corporate presentation deck.

A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.

\n\n\n \n\n \n\n \n\n \n\n\n

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n Exhibit \n Number \n	\n \n	\n Description \n
\n \n	\n \n	\n \n
\n 99.1 \n	\n \n	\n Corporate Presentation (October 2026). \n

\n 104 \n	\n \n	\n Cover Page Interactive Data File (embedded within the Inline XBRL Document). \n

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\n the undersigned hereunto duly authorized.

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n \n	\n PDS BIOTECHNOLOGY CORPORATION \n
\n \n	\n \n
\n Date: October 20, 2026 \n	\n By: \n \n	\n /s/ Frank Bedu-Addo, Ph.D. \n
\n \n	\n Name: Frank Bedu-Addo, Ph.D. \n
\n \n	\n Title: President and Chief Executive Officer \n

","zhKind","complete","PDSB","政策与监管","退市","IPO","aihot","/items/kzlwjdbbyx3z5qxlm1nshcopo","https://www.sec.gov/Archives/edgar/data/1472091/000114036126040283/0001140361-26-040283-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792800000&sig=a1281a539589308a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792800000&sig=57a86ea6a382db0f 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792800000&sig=f9807010575fb678 96w","changelogVersion","2026-10-01T08:00"]